Eclipse Bio

Eclipse Bio (Eclipsebio) is a life sciences company that provides RNA biology expertise and proprietary analytical technologies for drug developers and researchers. The company's eCOMPASS platform integrates AI-powered sequence design, rapid prototyping, and sequencing-first analytics into an iterative design-make-characterize workflow for RNA drug development. Eclipsebio offers a suite of proprietary assays including eSHAPE for RNA structure determination, m6A-eCLIP for methylation mapping, miR-eCLIP+ for miRNA binding identification, and Nanopore long-read sequencing, all providing nucleotide-level resolution. The company serves developers of RNA therapeutics, small oligonucleotides, small molecules targeting RNA, and AI training data for drug discovery through its eVERSE platform. Over 300 partners across pharma, biotech, and academia trust Eclipsebio's analytics. Founded in 2017 and headquartered in San Diego, California, the company has raised $18.9M in Series A funding from investors including Alexandria, Phoenix Venture Partners, and IGlobe Partners.